Pamidronate for DISH: Not Indicated
Pamidronate is not effective for treating diffuse idiopathic skeletal hyperostosis (DISH) and is not indicated for this condition. The FDA-approved indications for pamidronate are limited to hypercalcemia of malignancy, Paget's disease of bone, and osteolytic bone lesions from breast cancer or multiple myeloma 1.
Why Pamidronate Doesn't Work for DISH
Fundamental Disease Mechanism Mismatch
DISH is characterized by ossification and calcification of entheses (ligament and tendon insertion sites), particularly affecting the spine. This represents new bone formation rather than the excessive bone resorption that bisphosphonates target 2. Pamidronate works by:
- Inhibiting osteoclast activity and bone resorption
- Binding to bone surfaces during active resorption
- Disrupting the mevalonate pathway in osteoclasts 3
The problem: DISH involves pathological bone formation, not excessive resorption. Using an anti-resorptive agent for a disease of excessive formation is mechanistically illogical.
Evidence Limitations
The only published evidence regarding bisphosphonates and hyperostotic conditions comes from a 2021 case report on sternocostoclavicular hyperostosis (SCCH)—a different disease from DISH 4. This report:
- Describes only 2 patients
- Addresses SCCH, not DISH
- Provides anecdotal evidence without controlled comparison
- Cannot be extrapolated to DISH treatment
What Actually Matters in DISH
Recent research reveals that DISH is associated with:
- Degraded trabecular bone microstructure despite higher bone mineral density 5
- Genetic factors involving phosphate metabolism (ENPP1, PHEX pathways) 2
- Metabolic syndrome components (obesity, diabetes, hypertension) 5
Critical pitfall: The higher BMD seen in DISH patients might misleadingly suggest bisphosphonates could help, but the trabecular bone score shows actual bone quality deterioration 5. Pamidronate addresses neither the ossification process nor the underlying metabolic derangements.
Current Management Approach
Since pamidronate lacks efficacy for DISH, focus on:
- Symptomatic relief: NSAIDs for pain and stiffness
- Metabolic optimization: Address diabetes, obesity, and metabolic syndrome components
- Physical therapy: Maintain range of motion
- Surgical intervention: Reserved for mechanical complications (airway obstruction, dysphagia, spinal cord compression) 6
Bottom line: Do not prescribe pamidronate for DISH—it targets the wrong pathophysiology, has no supporting evidence for this indication, and is not FDA-approved for this use 1.